Volume 7: Issue 1

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

David B. Badesch, MD, SLC Chair, University of Colorado Health Sciences Center, Denver, Colorado
Robyn J. Barst, MD, SLC Immediate Past Chair, Columbia-Presbyterian Medical Center Babies Hospital, New York, New York
Vallerie V. McLaughlin, MD, SLC Vice-Chair, University of Michigan Health System, Ann Arbor, Michigan
Raymond L. Benza, MD, University of Alabama Health System, Birmingham, Alabama
Todd Bull, MD, University of Colorado Health Sciences Center, Denver, Colorado
Richard N. Channick, MD

This discussion was moderated by Karen A. Fagan, MD, Professor and Director, Division of Pulmonary Medicine, University of South Alabama College of Medicine, Mobile, Alabama. Panel members included Kamal K. Mubarak, MD, Assistant Professor of Medicine, Director, Pulmonary Hypertension Clinic, Wayne State University, Detroit, Michigan; Zeenat Safdar, MD, Assistant Professor of Medicine, Department of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Texas; Aaron Waxman, MD, PhD, Associate Professor of Medicine, Harvard Medical School, Director, Pulmonary Vascular Disease Program and Pulmonary Critical Care Unit, Massachusetts General Hospital, Boston, Massachusetts; and Roham T. Zamanian, MD, Assistant Professor of Medicine, Director, Adult Pulmonary Hypertension Clinical Service, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University School of Medicine, Stanford, California.

Guest Editor's Commentary

Introducing CME Credit– and More Dynamic Content

The Scientific Leadership Council of the Pulmonary Hypertension Association

David Badesch, MD, Outstanding Researcher, but First to Credit Team of Clinicians and Caregivers

International Corner

Evidence-based Medical Management of Pulmonary Hypertension 2008: Review of Updated 2007 ACCP Guidelines

Phase 2 and 3 Clinical Trials in Pulmonary Arterial Hypertension

Combination Therapies in Pulmonary Arterial Hypertension

Introduction

Guidelines for the Prevention of Central Venous Catheter-Related Bloodstream Infections with Prostanoid Therapy for Pulmonary Arterial Hypertension

Expanded Use of PAH Medications

Conference Abstracts

Guest Editor’s Memo

A Roundtable Discussion Addressing Patient-Centered Care and Quality of Life in Patients With Pulmonary Arterial Hypertension

Editor’s Memo

Pulmonary Hypertension Associated With Parenchymal Lung Disease